Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Metoprolol | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Metoprolol | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Metoprolol | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Metoprolol | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | | Metoprolol | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Metoprolol | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Metoprolol | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Metoprolol | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | | Metoprolol | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Metoprolol | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Metoprolol | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Metoprolol | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Metoprolol | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Metoprolol | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Metoprolol | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | | Metoprolol | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | | Metoprolol | hsa04064 | NF-kappa B signaling pathway | 7.24E-03 | 8 | O00463, P14778, Q04759, P07948, P06239, P24522, P09341, Q06643 | TRAF5, IL1R1, PRKCQ, LYN, LCK, GADD45A, CXCL1, LTB | More | | Metoprolol | hsa04071 | Sphingolipid signaling pathway | 6.08E-04 | 5 | P21453, Q9H228, P01375, Q13362, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | | Metoprolol | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Metoprolol | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | Metoprolol | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | Metoprolol | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Metoprolol | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Metoprolol | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Metoprolol | hsa04612 | Antigen processing and presentation | 9.02E-05 | 8 | P13765, P01730, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Metoprolol | hsa04613 | Neutrophil extracellular trap formation | 1.02E-04 | 8 | P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Metoprolol | hsa04640 | Hematopoietic cell lineage | 1.60E-04 | 10 | P13612, P14778, P27930, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, IL1R1, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | | Metoprolol | hsa04650 | Natural killer cell mediated cytotoxicity | 7.15E-06 | 10 | P01375, P06239, O60880, P20963, Q13241, P26718, O14931, P26717, Q14953, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | | Metoprolol | hsa04657 | IL-17 signaling pathway | 2.10E-03 | 5 | P49841, P19875, P14780, P80188, P01375 | GSK3B, CXCL2, MMP9, LCN2, TNF | More | | Metoprolol | hsa04658 | Th1 and Th2 cell differentiation | 2.44E-07 | 11 | Q04759, P07766, P20963, P09693, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Metoprolol | hsa04659 | Th17 cell differentiation | 4.63E-06 | 11 | Q04759, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Metoprolol | hsa04660 | T cell receptor signaling pathway | 8.91E-04 | 9 | Q04759, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | PRKCQ, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | | Metoprolol | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Metoprolol | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Metoprolol | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Metoprolol | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Metoprolol | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Metoprolol | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Metoprolol | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Metoprolol | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Metoprolol | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Metoprolol | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Metoprolol | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Metoprolol | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Metoprolol | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Metoprolol | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Metoprolol | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Metoprolol | hsa05146 | Amoebiasis | 6.83E-04 | 10 | P09341, P19875, P14778, P27930, P01375, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Metoprolol | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | | Metoprolol | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | Metoprolol | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Metoprolol | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Metoprolol | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Metoprolol | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.73E-03 | 6 | P07766, P20963, P09693, P06239, Q04759, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, CD4 | More | | Metoprolol | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Metoprolol | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Metoprolol | hsa05332 | Graft-versus-host disease | 9.58E-04 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | | Metoprolol | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | | |